Practice Performance Partners

Photobiomodulation has created significant interest as a noninvasive intervention for patients with nonexudative AMD. It has also created questions about mechanism, patient selection, clinical benefit, and the strength of the available evidence.

This course examines the proposed mitochondrial and cellular mechanisms of photobiomodulation, the LIGHTSITE clinical trials, treatment protocols, safety, and the patient population represented in the evidence. We will distinguish reported visual-acuity outcomes from exploratory anatomic findings involving drusen and geographic atrophy.

You will learn how to:

• Explain the proposed mechanism of photobiomodulation
• Interpret the major LIGHTSITE findings
• Identify patients who most closely resemble studied populations
• Evaluate visual, functional, and anatomic outcomes separately
• Distinguish device-specific evidence from assumptions about red-light therapy as a class
• Place photobiomodulation within a comprehensive AMD-management strategy

The clinical question is not whether light can affect retinal biology. It is how confidently the current evidence can be applied to an individual patient.

Enroll now and evaluate photobiomodulation with a clinically balanced approach.